默克Dr Dave Maraldo:小分子平台敏捷性可为生物制品生产提供借鉴
Small-Molecule Agility Can Inform Biologics Manufacturing, Says Merck
默克制造部门执行副总裁兼总裁Dr Dave Maraldo表示,小分子平台敏捷性与灵活的偶联产能可帮助生物制品生产响应研究需求。他指出小分子工厂将单元操作视为可互换并按分子需要排序,生物制品可朝此方向推进;资本投资应围绕核心技术布局,使网络在研究者反馈分子对不锈钢敏感、需改用一次性袋时能够响应。
Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.
In the second segment of an interview with BioPharm International®, Dave Maraldo, PhD, executive vice president and president of Merck Manufacturing Division, examines what biologics manufacturing can learn from small-molecule plants and how capital investment can preserve flexibility for bioconjugation. Both points centered on how platform thinking can carry across molecule types.
"I would frame it as, as research focuses on what the biology or the chemistry of a molecule requires, manufacturing can be responsive to that trial and error to be able to accelerate the molecule once we land on the particular process."
Dr Maraldo says small-molecule manufacturing offers lessons in platform agility for biologics. Small-molecule facilities treat unit operations as interchangeable, such as roller compaction or wet granulation, and sequence them based on what each molecule needs. He emphasizes that biologics can head in that direction. Purifying and then conjugating a peptide or an antibody, for example, is still bioconjugation. He also asks what small molecules can teach biologics about platform agility, while noting that biologics carry many sensitivities and differences.
How can capital investment keep bioconjugation flexible?
Asked whether this investment strategy amounts to a trial-and-error approach, Dr Maraldo says that it links to core technologies, and conjugation is key know-how. Many methods exist, he emphasizes. Manufacturers can conjugate in a stainless-steel reactor or in a single-use assembly. The challenge, he notes, is to structure capital investment so the network can respond when researchers report that a molecule is sensitive to stainless steel and needs a bag.
"I would frame it as, as research focuses on what the biology or the chemistry of a molecule requires, manufacturing can be responsive to that trial and error to be able to accelerate the molecule once we land on the particular process," he explains.
Some capabilities already overlap between the 2 worlds, he says. Many small-molecule programs, and the wider industry, use enzymes, and producing an enzyme involves an Escherichia coli fermentation, a form of cell culture. Dr Maraldo points out that those capabilities are quite analogous between small molecules and large molecules. Those shared capabilities show where learning can transfer, he adds.
Learn more from the first segment of Dr Maraldo’s interview. To gain more insight on Merck, watch an exclusive interview with Dr Maraldo on Pharmaceutical Executive, a sister brand under MJH Life Sciences.
About the speaker
Dave Maraldo, PhD, Executive Vice President and President, Merck Manufacturing Division
Dr Maraldo has responsibility for Merck’s worldwide human health manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines and biologics. Since joining the company as a project engineer in 1999, he progressed through a range of leadership roles across manufacturing, technical operations, commercialization and integrated development and supply. Building on that foundation, he led global biologics operations from 2022- 2025 and most recently served as senior vice president of human health manufacturing. Dr Maraldo earned his PhD and master of chemical engineering degrees from Drexel University, an MBA degree from Lehigh University and a bachelor of chemical engineering degree from Widener University.
Related to this article
November 13th, 2026
Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.
November 17th, 2026
Galinpepimut-S maintenance extended median overall survival to 24.0 vs 14.7 months in transplant-ineligible AML patients in second or later remission.
November 13th, 2026
Donidalorsen sustained a 95% reduction in hereditary angioedema attacks over 2 years, and patients switching from other prophylaxis saw a 71% drop.
November 13th, 2026
A single 240 mg dose of WVE-007 cut visceral fat while preserving lean mass for 1 year, as Activin E fell by up to 88% across INLIGHT dose groups.
November 10th, 2026
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
November 17th, 2026
Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.
November 17th, 2026
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
November 17th, 2026
Mazen Noureddin, MD, MHSc, discusses phase 2 data for GSK’s once-monthly efimosfermin presented at The Liver Meeting 2026, including fibrosis marker results in patients with compensated cirrhosis.
来源:BioPharm International · biopharminternational.com







